CROMSOURCE Supports Italian Cystic Fibrosis Society's Clinical Research Training Initiative
CROMSOURCE announced that it is delivering several modules of a training course on clinical research best practice organized by the SIFC.
CROMSOURCE, an international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, today announced that it is delivering several modules of a training course on clinical research best practice organized by the SIFC (Italian Cystic Fibrosis Society). The course commenced in December 2014 and will complete in February 2015.
Effective development of therapies in rare diseases such as cystic fibrosis relies on the involvement of physicians working in specialized clinics. These clinicians are then able to offer participation in such research projects to patients under their care. By offering training in clinical research best practice, SIFC hopes that physicians and their teams may be able to engage even more in future clinical research programs and offer participation to more patients with cystic fibrosis.
As recognized experts in clinical research, with strong experience in cystic fibrosis, CROMSOURCE is well-placed to support this work. During the course, CROMSOURCE personnel are training physicians and their teams on topics including typical aspects of a clinical research study protocol, the responsibilities of the physician and clinical staff who are involved in clinical research and the regulatory application and approval process for clinical research.
Oriana Zerbini MD, founder and Chief Executive Officer of CROMSOURCE noted, "We are delighted to take part in this initiative and work alongside representatives from the Italian ISS (National High Health Commission), the US Cystic Fibrosis Foundation, Ethics Committees and various pharmaceutical companies. CROMSOURCE is committed to sharing our expertise in clinical research and fully recognize the importance of this training course. In this spirit we have pleasure in supporting this important initiative".
About CROMSOURCE: Founded in 1994, CROMSOURCE is the leading independent provider of international outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions across Europe and North America. CROMSOURCE is unique in providing clients with a guarantee that projects will be delivered according to agreed timelines and within the original contract budget.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
